Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus

British Journal of Cardiology

Volumn 18, Issue 1, 2011, Pages 37-45

  MacLean, Alexandra ^a   McKenney, James M ^a   Scott, Russell ^a   Brinton, Eliot ^a   Bays, Harold E ^a   Mitchel, Yale B ^a   Paolini, John F ^a   Giezek, Hilde ^a   Vandormael, Kristel ^a   Ruck, Rae Ann ^a   Gibson, Kendra ^a   Sisk, Christine McCrary ^a   Maccubbin, Darbie L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIGUANIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAROPIPRANT; NICOTINIC ACID; SULFONYLUREA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ASSESSMENT; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUSHING; HUMAN; HYPERGLYCEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRURITUS; RHABDOMYOLYSIS; SIDE EFFECT; VOMITING;

EID: 79952747843     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68-S71.
2. Manzato E, Zambon A, Lapolla A et al. Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care 1993;16:469-75. (Pubitemid 23046638)
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
4. Grundy SM, Cleeman JI, Merz NB et al. Implications of recent clinical trials for the national cholesterol education program. Adult treatment panel III guidelines. Circulation 2004;110:227-39. (Pubitemid 38924592)
5. Genest J, Frolich J, Fodor G, McPherson R, the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003;169:921-4. (Pubitemid 37372465)
6. Lewin A, Kipnes M, Meneghini L et al.; Simvastatin/Thiazolidinedione Study Group. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2004;26:379-89. (Pubitemid 38457331)
7. Freed MI, Ratner R, Marcovina SM et al.; Rosiglitazone Study 108 investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-52. (Pubitemid 35232617)
8. Guyton JR, Blazing MA, Hagar J et al.; for the Niaspan-Gemfibrozil Study Group. Extended-release niacin versus gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med 2000;160:1177-84. (Pubitemid 30227029)
9. The coronary drug project. JAMA 1972;221:918.
10. Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. (Pubitemid 33126837)
11. Brown BG, Hillger L, Zhao XQ, Poulin D, Albers JJ. Types of change in coronary stenosis severity and their relative importance in overall progression and regression in coronary disease. Observations from the FATS trial. Familial Atherosclerosis Treatment study. Ann NY Acad Sci 1995;748:407-17.
12. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
13. Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55. (Pubitemid 17208898)
14. Capuzzi DM, Morgan JM, Brusco OAJ, Intenzo CM. Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep 2000;2:64-71.
15. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99(suppl):22C-31C.
16. Knopp RH, Ginsberg J, Albers JJ et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-50. (Pubitemid 15036921)
17. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004;62:229-34. (Pubitemid 39193956)
18. Illingworth DR, Stein EA, Mitchel YB et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994;154:1586-95. (Pubitemid 24242345)
19. Mills E, Prousky J, Raskin G et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial. BMC Clin Pharmacol 2003;3:4-11.
20. Kamal-Bahl SJ, Burke T, Watson DJ, Wentworth CE. Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin 2008;24:1817-21. (Pubitemid 351929079)
21. Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006;103:6682-7.
22. Sturino CF, O'Neill G, Lachance N et al. Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007;50:794-806. (Pubitemid 46332991)
23. Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients. Am J Cardiol 2008;101:625-30.
24. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control - National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Laboratory Med 1989;9:105-35. (Pubitemid 19070302)
25. Fridewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
26. Haffner SM, Alexander CM, Cook TJ et al.; for the Scandinavian Simvastatin Survival Study Group. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med 1999;159:2661-7.
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-16.
28. Colhoun HM, Betteridge DJ, Durrington PN et al.; on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96. (Pubitemid 39140624)
29. Sever PS, Dahlöf B, Poulter NR et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58. (Pubitemid 36398384)
30. Cannon CP, Braunwald E, McCabe CH et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
31. Miller NE, Thelle DS, Førde OH, Mjøs OD. The Tromsø Heart Study. High-density lipoprotein and coronary heart disease: a prospective case-control study. Lancet 1977;1:965-8.
32. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
33. Barter P, Gotto A, LaRosa J et al.; on behalf of the TNT Steering Committee and Investigators. On-treatment levels of HDL-C and the ratio of LDL-C/HDL-C as predictors of cardiovascular events in the treating to new targets (TNT) study. J Am Coll Cardiol 2006;47:298A.
34. Maccubbin D, Bays HE, Olsson AG et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70.
35. Zhao X-Q, Yuan C, Hatsukami TS et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 2001;21:1623-9. (Pubitemid 34215582)
36. Canner PL, Furberg CD, McGovern ME. Niacin decreases myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the Coronary Drug Project [Abstract 3138]. Circulation 2002;106(suppl II):636.
37. Morse JS, Brown BG, Zhao X-Q et al. Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDL-C and diabetes mellitus or impaired fasting glucose [Abstract 842-3]. J Am Coll Cardiol 2001;37(suppl A):262A.
38. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81:26B-31B.
39. Lamarche B, Moorjani S, Lupien PJ et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94:273-8. (Pubitemid 26266109)
40. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43. (Pubitemid 30165206)
41. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65. (Pubitemid 35315836)
42. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:426-62.
43. Pietila KO, Harmoinen AP, Jokinitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996;17:1345-9. (Pubitemid 26306662)
44. Grundy SM, Lenza Vega G, McGovern ME et al.; Diabetes Multicenter Research Group. Efficacy, safety and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002;162:1568-76. (Pubitemid 34765005)
45. Kuvin JT, Dave DM, Sliney KA et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98:743-5. (Pubitemid 44301006)
46. Thoenes M, Oguchi A, Nagamia S et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 2007;61:1942-8. (Pubitemid 47573105)
47. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER 2). A double blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17. (Pubitemid 39612564)
48. Taylor AJ, Sullenberger LE, Lee HJ. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50. (Pubitemid 44789989)
49. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-6. (Pubitemid 20246864)
50. Elam MB, Hunninghake DB, Davis K et al. Niacin favorably affects plasma lipid and lipoprotein levels with minimal effects on glycemic control in diabetic subjects. JAMA 2000;284:1263-70.
51. Skyler JS, Bergenstal R, Bonow RO et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation 2009;119:351-7.